Novo Nordisk A/S
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
Inclusion Criteria: * Male or female (sex at birth). * Age 18-55 years (both inclusive) at the time of signing informed consent. * Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator. * Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Previous…
NNC0721-8060 will be administered subcutaneously.
Semaglutide will be administered subcutaneously.
Placebo will be administered subcutaneously.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.